This bill amends sections 44-4606 and 44-4610 of the Revised Statutes Cumulative Supplement, 2024, to enhance protections for patients and pharmacies regarding clinician-administered drugs and the operations of pharmacy benefit managers (PBMs). It prohibits certain actions by insurance policies and health plans, such as refusing to authorize payment for clinician-administered drugs, imposing additional fees for obtaining these drugs from authorized providers, and limiting patient choice in selecting providers. The bill also establishes that PBMs cannot restrict how retail community pharmacies dispense or deliver prescription drugs and must allow pharmacies to participate in specialty pharmacy networks if they meet reasonable accreditation requirements.

Additionally, the bill introduces new provisions that ensure transparency and fair practices in the relationship between pharmacies and PBMs. It prohibits PBMs from penalizing pharmacies for disclosing information about their practices and requires that any terms for participation in specialty pharmacy networks be reasonable, avoiding excessive fees or burdensome reporting requirements. The bill includes a severability clause, ensuring that if any part is found unconstitutional, the remaining sections will still be valid. The original sections 44-4606 and 44-4610 are repealed as part of this legislative update.

Statutes affected:
Introduced: 44-4606, 44-4610